AMPLY Discovery Secures $1.75M Seed Round to Accelerate AI-Driven Breakthroughs in Biologics and Nutraceuticals

AMPLY Discovery is thrilled to announce that it has successfully raised $1,750,000 in a funding round designed to propel its innovative mission even further. As a pioneering biopharmaceutical startup headquartered in Belfast, Northern Ireland, and spun out from Queen’s University Belfast, AMPLY Discovery is transforming the way novel biologics and nutraceutical candidates are discovered. By harnessing the power of machine learning and synthetic biology, the company leverages vast amounts of biological data through its proprietary in silico and in vitro hybrid platform to identify best-in-class molecules. This unique approach not only reflects its commitment to evolving solutions that nature itself has long perfected—"Novel Biologics, Designed by Evolution. Discovered by AI"—but also positions the company at the forefront of tackling some of humankind’s most pressing challenges, including cancer, multidrug-resistant infections, and metabolic diseases. The capital infusion will be directed toward enhancing the company’s data analytics engines and expanding its laboratory capabilities, ensuring that its research and development pipeline remains robust and agile. This funding is also expected to bolster strategic collaborations and accelerate the translation of laboratory discoveries to clinical candidates. AMPLY Discovery’s vision emphasizes the seamless integration of artificial intelligence in bioprospecting, aiming to streamline drug discovery processes and reduce the time required to bring innovative therapies to market. With this investment, AMPLY Discovery is not only affirming its presence as a next-generation biotech pioneer but also reinforcing its commitment to improving global health outcomes by harnessing cutting-edge technology to unlock the hidden potential of nature’s blueprints.